See What HealthDay Can Do For You
Contact Us

β-Lactams May Be Best Choice for Soft Tissue Infection

Fewer adverse effects and same efficacy compared to fluoroquinolones

TUESDAY, Dec. 12 (HealthDay News) -- It may be best to treat skin and soft tissue infections with β-lactams rather than fluoroquinolones, according to a study published in the December issue of the Mayo Clinic Proceedings.

Matthew E. Falagas, M.D., M.Sc., of the Alfa Institute of Biomedical Sciences in Athens, Greece, and colleagues conducted a meta-analysis of 20 randomized controlled trials comprising 4,817 patients.

Overall, fluoroquinolones were moderately more effective, with a 90.4 percent success rate compared to 88.2 percent for β-lactams. However, they were associated with more side effects, in 19.2 percent of cases versus 15.2 percent for the β-lactams.

In patients with moderate-to-severe infections the efficacy of both drugs was the same, and there was also no difference between the two drugs in patients who were not prescribed third-generation cephalosporins, or for those patients who were microbiologically evaluable.

"These facts, in association with the increasing incidence of methicillin-resistant Stapholococcus aureus strains resistant to fluoroquinolones, suggest that fluoroquinolone use is not associated with substantial advantages when compared with β-lactams for empirical treatment of skin and soft tissue infections," the authors conclude.

Abstract
Full Text (subscription or payment may be required)

Physician's Briefing

HealthDay

HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.